Beyond the test result
Mayo Clinic Laboratories combines the expertise of world-renowned laboratorians and physicians to provide answers for patients’ serious and complex medical challenges.
These are the stories of the people throughout that journey — from the laboratorians conducting tests and delivering results, to the physicians guiding diagnosis and treatment, to the patients worldwide who need answers.
This week's research roundup features a study on bipolar disorder cases that provide a new insight into underlying biology.
Top highlights include: Unvaccinated people at highest risk being infected by delta variant, strong immune response underlying kidney injury related to Covid, having certain type of antibodies help Covid patients avoid hospitalization, and you are you hesitant about Covid vaccine development?
For the last year, Emily Fernholz’s time has been consumed by COVID-19. But as the pandemic has eased, she’s turned her attention back to the usual business of Mayo’s Clinical Virology/Parasitology Laboratory: testing for virus-, parasite-, and vector-borne diseases.
This week's research roundup features a study on the prognostic role of MYC structural variants identified by NGS and FISH in multiple myeloma.
Top highlights include: Changes to outpatient visitor restrictions in Rochester, MN, Mayo Clinic Q&A podcast on the COVID-19 delta variant, and respiratory illnesses on the rise with symptoms similar to COVID-19.
Mayo Clinic renal pathologist Dr. Sanjeev Sethi identified NELL-1 as a biomarker for membranous nephropathy (MN) in 2019. Two years later, Dr. Sethi helped implement the first ever IHC test to detect NELL-1 antigen, which appears in about 10% of MN patients and is linked to underlying malignancy.
This week’s research roundup features a study on acute treatments for episodic migraine in adults: A systematic review and meta-analysis.
Topic includes: new vaccine platform invented by Mayo enters COVID-19 clinical trial, Q&A on vaccination and precautions and the new work-life balancing act.
Mayo Clinic’s Advanced Diagnostics Laboratory (ADL) is a visionary space designed to foster innovation. The ADL has a direct impact on patient lives, bringing promising tests and services to patients at Mayo and around the world.
Shawn Mitchell brings a wealth of laboratory expertise to his role as a senior product manager at Mayo Clinic Laboratories, where he puts his knowledge to work promoting Mayo’s innovative infectious disease testing.
This week’s research roundup features a study on how ciliopathy protein HYLS1 coordinates the biogenesis and signaling of primary cilia by activating the ciliary lipid kinase PIPKIγ.